Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: A perspective

Journal of Bone and Mineral Research

Volumn 23, Issue 8, 2008, Pages 1155-1167

  Bouxsein, Mary L ^a,c   Delmas, Pierre D ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITÉ DE LYON   (France)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Biomarker; Clinical trial; Fracture; Osteoporosis; Surrogate endpoint

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE;

BONE BIOPSY; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHICS; FINITE ELEMENT ANALYSIS; FOLLOW UP; FRAGILITY FRACTURE; HORMONE SUBSTITUTION; HUMAN; MORBIDITY; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; REVIEW; RISK REDUCTION; TRABECULAR BONE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 47849112159     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080301     Document Type: Review

References (160)

1. Rosen CJ 2005 Clinical practice. Postmenopausal osteoporosis. N Engl J Med 353:595-603.
2. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008.
3. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022.
4. Committee for Medicinal Products for Human Use 2006 Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. European Medicines Agency, London, UK.
5. Food and Drug Administration 1994 Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treament of Postmenopausal Osteoporosis Food and Drug Administration, Washington, DC, USA.
6. Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY 2002 The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1-5.
7. Brody BA, Dickey N, Ellenberg SS, Heaney RP, Levine RJ, O'Brien RL, Purtilo RB, Weijer C 2003 Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis? J Bone Miner Res 18:1105-1109.
8. Berns B, Démolis P, Scheulen M 2007 How can biomarkers become surrogate endpoints? Eur J Cancer 5:37-40.
9. Biomarkers Definitions Working Group 2001 Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95.
10. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL 2001 Considerations in the evaluation of surrogate endpoints in clinical trials, summary of a National Institutes of Health workshop. Control Clin Trials 22:485-502.
11. Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, Bruyere O, Calvo G, Devogelaer JP, Dreiser RL, Herrero-Beaumont G, Kahan A, Kreutz G, Laslop A, Lemmel EM, Nuki G, Van De Putte L, Vanhaelst L, Reginster JY 2004 Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 12:263-268.
12. Temple R 1999 Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282:790-795.
13. Palmeri S 2007 Clincal surrogate endpoints. Eur J Cancer 5:44-45.
14. Alonso A, Molenberghs G, Burzykowski T, Renard D, Geys H, Shkedy Z, Tibaldi F, Abrahantes JC, Buyse M 2004 Prentice's approach and the meta-analytic paradigm: A reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 60:724-728.
15. Wagner JA, Williams SA, Webster CJ 2007 Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 81:104-107.
16. Prentice RL 1989 Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431-440.
17. Freedman LS, Graubard BI, Schatzkin A 1992 Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167-178.
18. Lin DY, Fleming TR, De Gruttola V 1997 Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 16:1515-1527.
19. Buyse M, Molenberghs G 1998 Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029.
20. Hughes MD 2002 Evaluating surrogate endpoints. Control Clin Trials 23:703-707.
21. Lassere M, Johnson K, Hughes M, Altman D, Buyse M, Galbraith S, Wells G 2007 Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches. J Rheumatol 34:616-619.
22. Daniels MJ, Hughes MD 1997 Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16:1965-1982.
23. Gail MH, Pfeiffer R, Van Houwelingen HC, Carroll RJ 2000 On meta-analytic assessment of surrogate outcomes. Biostatistics 1:231-246.
24. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H 2000 The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1:49-67.
25. Alonso A, Molenberghs G, Geys H, Buyse M, Vangeneugden T 2006 A unifying approach for surrogate marker validation based on Prentice's criteria. Stat Med 25:205-221.
26. Xu J, Zeger SL 2001 The evaluation of multiple surrogate endpoints. Biometrics 57:81-87.
27. Alonso A, Molenberghs G 2007 Surrogate marker evaluation from an information theory perspective. Biometrics 63:180-186.
28. Baker SG, Kramer BS 2003 A perfect correlate does not a surrogate make. BMC Med Res Methodol 3:16.
29. Bouxsein ML 2005 Determinants of skeletal fragility. Best Pract Res Clin Rheumatol 19:897-911.
30. Seeman E, Delmas PD 2006 Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250-2261.
31. Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259.
32. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A 2005 Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194.
33. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538.
34. Bouxsein ML, Palermo L, Yeung C, Black DM 2002 Digital X-ray radiogrammetry predicts hip, wrist and vertebral fracture risk in elderly women: A prospective analysis from the study of osteoporotic fractures. Osteoporos Int 13:358-365.
35. Prentice R 1986 A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73:1-11.
36. Moro M, Hecker AT, Bouxsein ML, Myers ER 1995 Failure load of thoracic vertebrae correlates with lumbar bone mineral density measured by DXA. Calcif Tissue Int 56:206-209.
37. Cheng XG, Lowet G, Boonen S, Nicholson PH, Brys P, Nijs J, Dequeker J 1997 Assessment of the strength of proximal femur in vitro: Relationship to femoral bone mineral density and femoral geometry. Bone 20:213-218.
38. Bouxsein ML, Coan BS, Lee SC 1999 Prediction of the strength of the elderly proximal femur by bone mineral density and quantitative ultrasound measurements of the heel and tibia. Bone 25:49-54.
39. Lochmuller EM, Burklein D, Kuhn V, Glaser C, Muller R, Gluer CC, Eckstein F 2002 Mechanical strength of the thoracolumbar spine in the elderly: Prediction from in situ dual-energy X-ray absorptiometry, quantitative computed tomography (QCT), upper and lower limb peripheral QCT, and quantitative ultrasound. Bone 31:77-84.
40. Lochmuller EM, Muller R, Kuhn V, Lill CA, Eckstein F 2003 Can novel clinical densitometric techniques replace or improve DXA in predicting bone strength in osteoporosis at the hip and other skeletal sites? J Bone Miner Res 18:906-912.
41. Eckstein F, Lochmuller EM, Lill CA, Kuhn V, Schneider E, Delling G, Muller R 2002 Bone strength at clinically relevant sites displays substantial heterogeneity and is best predicted from site-specific bone densitometry. J Bone Miner Res 17:162-171.
42. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES 2006 BMD and risk of hip and nonvertebral fractures in older men: A prospective study and comparison with older women. J Bone Miner Res 21:1550-1556.
43. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ III, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N 2007 The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033-1046.
44. Cummings SR, Bates D, Black DM 2002 Clinical use of bone densitometry: Scientific review. JAMA 288:1889-1897.
45. Lindsay R 1987 Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 156:1347-1351.
46. Ettinger B 1993 Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis. Clin Ther 15:950-962.
47. Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP, Delmas PD 1999 Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteoporos Int 9:358-366.
48. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
49. Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S 1994 Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837.
50. Chesnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC 1995 Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152.
51. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443.
52. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr 1998 Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83:396-402.
53. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340.
54. Ravn P, Clemmesen B, Riis BJ, Christiansen C 1996 The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19:527-533.
55. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH 1997 Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307.
56. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060-2066.
57. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468.
58. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822.
59. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R 2003 Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212-5220.
60. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
61. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254.
62. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236.
63. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289.
64. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10.
65. Li Z, Meredith MP, Hoseyni MS 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175-3188.
66. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592.
67. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401.
68. Delmas P, Seeman E 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604.
69. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH 2006 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21:1785-1790.
70. Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY 2007 Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 92:3076-3081.
71. Bruyere O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY 2007 Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 23:3041-3045.
72. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD 1996 Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349.
73. Sherman SS, Tobin JD, Hollis BW, Gundberg CM, Roy TA, Plato CC 1992 Biochemical parameters associated with low bone density in healthy men and women. J Bone Miner Res 7:1123-1130.
74. Stepan JJ 2000 Prediction of bone loss in postmenopausal women. Osteoporos Int 11(Suppl 6):S45-S54.
75. Christiansen C, Riis BJ, Rodbro P 1987 Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105-1108.
76. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL 1996 Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 59:328-333.
77. Ross PD, Knowlton W 1998 Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 13:297-302.
78. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD 1999 Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res 14:1614-1621.
79. Lofman O, Magnusson P, Toss G, Larsson L 2005 Common biochemical markers of bone turnover predict future bone loss: A 5-year follow-up study. Clin Chim Acta 356:67-75.
80. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P 2007 Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 18:1297-1305.
81. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15:1526-1536.
82. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA 2000 Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporos Int 11:76-82.
83. Garnero P, Cloos P, Sornay-Rendu E, Qvist P, Delmas P 2002 Type I collagen racemization and isomerization and the irsk of fracture in postmenopausal women: The OFELY prospective study. J Bone Miner Res 17:826-833.
84. Bruyere O, Collette J, Delmas P, Rouillon A, Roux C, Seidel L, Richy F, Reginster JY 2003 Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44:259-265.
85. Melton LJ III, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL 2003 Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 18:312-318.
86. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Vaananen HK, Akesson K, Obrant KJ 2004 Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386-393.
87. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD 2005 Identification of osteopenic women at high risk of fracture: The OFELY study. J Bone Miner Res 20:1813-1819.
88. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA 2005 Bone resorption and osteoporotic fractures in elderly men: The dubbo osteoporosis epidemiology study. J Bone Miner Res 20:579-587.
89. Ivaska KK, Gerdhem P, Akesson K, Obrant KJ 2007 Bone turnover markers and prediction of fracture: Nine year follow-up study of 1040 elderly women. J Bone Miner Res 22:S1;S21.
90. Chapurlat RD, Garnero P, Brart G, Meunier PJ, Delmas PD 2000 Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: The EPIDOS study. Bone 27:283-286.
91. Chen JS, Seibel MJ, Zochling J, March L, Cameron ID, Cumming RG, Schwarz J, Simpson JM, Sambrook PN 2006 Calcaneal ultrasound but not bone turnover predicts fractures in vitamin D deficient frail elderly at high risk of falls. Calcif Tissue Int 79:37-42.
92. Garnero P, Dargent-Molina P, Hans D, Schott AM, Breart G, Meunier PJ, Delmas PD 1998 Do markers of bone resorption add to bone mineral density and ultrasonographic heel mea-surement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 8:563-569.
93. van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, Birkenhager JC, Pols HA 1996 Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study. BMJ 312:482-483.
94. Delmas PD, Pornel B, Felsenberg D, Garnero P, Hardy P, Pilate C, Dain MP 1999 A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group. Bone 24:517-523.
95. Prestwood KM, Kenny AM, Unson C, Kulldorff M 2000 The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: A randomized, double blind, placebo-controlled study. J Clin Endocrinol Metab 85:4462-4469.
96. Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, DeBrock J, Ricerca E, Chesnut CH III 1993 The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1406.
97. Christiansen C, Tanko LB, Warming L, Moelgaard A, Christgau S, Qvist P, Baumann M, Wieczorek L, Hoyle N 2003 Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int 14:609-613.
98. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831.
99. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822.
100. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495-502.
101. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555.
102. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemi-cal markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970.
103. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM 2006 Short-term Changes in Bone Turnover Markers and Bone Mineral Density Response to Parathyroid Hormone in Postmenopausal Women with Osteoporosis. J Clin Endocrinol Metab.
104. Delmas P, Watts NB, Miller P, Cahall D, Bilezikian J, Lindsay R 2007 Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: The OPTAMISE study. J Bone Miner Res 22:S1;S27.
105. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930.
106. Eastell R, Barton I, Hannon R, Chines A, Garnero P, Delmas P 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056.
107. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351.
108. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The fracture intervention trial. J Bone Miner Res 19:1250-1258.
109. Eastell R, Hannon RA, Garnero P, Campbell MJ, Delmas PD 2007 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: Review of statistical analysis. J Bone Miner Res 22:1656-1660.
110. Delmas PD, Li Z, Cooper C 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330-337.
111. Bouxsein M 2007 Biomechanics of age-related fractures. In: Marcus R, Feldman D, Nelson D, Rosen C (eds.) Osteoporosis, 3rd ed., vol. I. Elsevier Academic Press, San Diego, CA, USA, pp. 601-616.
112. Lang TF, Keyak JH, Heitz MW, Augat P, Lu Y, Mathur A, Genant HK 1997 Volumetric quantitative computed tomography of the proximal femur: Precision and relation to bone strength. Bone 21:101-108.
113. Cody DD, Gross GJ, Hou FJ, Spencer HJ, Goldstein SA, Fyhrie DP 1999 Femoral strength is better predicted by finite element models than QCT and DXA. J Biomech 32:1013-1020.
114. Bousson V, Le Bras A, Roqueplan F, Kang Y, Mitton D, Kolta S, Bergot C, Skalli W, Vicaut E, Kalender W, Engelke K, Laredo JD 2006 Volumetric quantitative computed tomography of the proximal femur: Relationships linking geometric and densitometric variables to bone strength. Role for compact bone. Osteoporos Int 17:855-864.
115. Brinckmann P, Biggeman M, Hilweg D 1989 Prediction of the compressive strength of human lumbar vertebrae. Clin Biomech (Bristol, Avon) 4:S1-S27.
116. Cheng XG, Nicholson PH, Boonen S, Lowet G, Brys P, Aerssens J, Van der Perre G, Dequeker J 1997 Prediction of vertebral strength in vitro by spinal bone densitometry and calcaneal ultrasound. J Bone Miner Res 12:1721-1728.
117. Eckstein F, Fischbeck M, Kuhn V, Link TM, Priemel M, Lochmuller EM 2004 Determinants and heterogeneity of mechanical competence throughout the thoracolumbar spine of elderly women and men. Bone 35:364-374.
118. Crawford RP, Brouwers J, Keaveny TM 2004 Accurate prediction of vertebral strength using voxel-based non-linear finite element models. Trans Orthop Res 29:1123.
119. Buckley JM, Cheng L, Loo K, Slyfield C, Xu Z 2007 Quantitative computed tomography-based predictions of vertebral strength in anterior bending. Spine 32:1019-1027.
120. Buckley JM, Loo K, Motherway J 2007 Comparison of quantitative computed tomography-based measures in predicting vertebral compressive strength. Bone 40:767-774.
121. Mackey DC, Eby JG, Harris F, Taaffe DR, Cauley JA, Tylavsky FA, Harris TB, Lang TF, Cummings SR 2007 Prediction of clinical non-spine fractures in older black and white men and women with volumetric BMD of the spine and areal BMD of the hip: The Health, Aging, and Body Composition Study*. J Bone Miner Res 22:1862-1868.
122. Ott SM, Kilcoyne RF, Chestnut CH 1987 Ability of four different techniques of measuring bone mass to diagnose vertebral fractures in postmenopausal women. J Bone Miner Res 2:201-210.
123. Cody DD, Hou FJ, Divine GW, Fyhrie DP 2000 Femoral structure and stiffness in patients with femoral neck fracture. J Orthop Res 18:443-448.
124. Bergot C, Laval-Jeantet AM, Hutchinson K, Dautraix I, Caulin F, Genant HK 2001 A comparison of spinal quantitative computed tomography with dual energy X-ray absorptiometry in European women with vertebral and nonvertebral fractures. Calcif Tissue Int 68:74-82.
125. Lang TF, Guglielmi G, van Kuijk C, De Serio A, Cammisa M, Genant HK 2002 Measurement of bone mineral density at the spine and proximal femur by volumetric quantitative computed tomography and dual-energy X-ray absorptiometry in elderly women with and without vertebral fractures. Bone 30:247-250.
126. Rehman Q, Lang T, Modin G, Lane NE 2002 Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy. Arthritis Rheum 46:1292-1297.
127. Cheng X, Li J, Lu Y, Keyak J, Lang T 2007 Proximal femoral density and geometry measurements by quantitative computed tomography: Association with hip fracture. Bone 40:169-174.
128. Melton LJ, Riggs BL, Keaveny TM, Achenbach SJ, Hoffmann PF, Camp JJ, Rouleau PA, Bouxsein ML, Amin S, Atkinson EJ, Robb RA, Khosla S 2007 Structural determinants of vertebral fracture risk. J Bone Miner Res 22:1885-1892.
129. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE 2003 Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 14:77-81.
130. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
131. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226.
132. Genant HK, Lang T, Fuerst T, Pinette KV, Zhou C, Thiebaud D, Diez-Perez A 2004 Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. Bone 35:1164-1168.
133. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768.
134. Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C, Gluer CC 2007 Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study. J Bone Miner Res 22:1426-1433.
135. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565.
136. Parfitt A 1984 Age-related structural changes in trabecular and cortical bone: Cellular mechanicsms and biomechanical consequences. Calcif Tissue Int 36(Suppl):123-128.
137. Parfitt A 1987 Trabecular bone architecture in the pathogenesis and prevention of fracture. Am J Med 82:68-72.
138. Parfitt AM 1992 Implications of architecture for the pathogenesis and prevention of vertebral fracture. Bone 13(Suppl 2):S41-S47.
139. Aaron JE, Shore PA, Shore RC, Beneton M, Kanis JA 2000 Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: II. Three-dimensional histology. Bone 27:277-282.
140. Hordon LD, Raisi M, Aaron JE, Paxton SK, Beneton M, Kanis JA 2000 Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: I. Two-dimensional histology. Bone 27:271-276.
141. Legrand E, Chappard D, Pascaretti C, Duquenne M, Krebs S, Rohmer V, Basle MF, Audran M 2000 Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis. J Bone Miner Res 15:13-19.
142. Majumdar S, Link TM, Augat P, Lin JC, Newitt D, Lane NE, Genant HK 1999 Trabecular bone architecture in the distal radius using magnetic resonance imaging in subjects with frac-tures of the proximal femur. Magnetic Resonance Science Center and Osteoporosis and Arthritis Research Group. Osteoporos Int 10:231-239.
143. Link TM, Majumdar S, Augat P, Lin JC, Newitt D, Lu Y, Lane NE, Genant HK 1998 In vivo high resolution MRI of the calcaneus: Differences in trabecular structure in osteoporosis patients. J Bone Miner Res 13:1175-1182.
144. Link TM, Vieth V, Matheis J, Newitt D, Lu Y, Rummeny EJ, Majumdar S 2002 Bone structure of the distal radius and the calcaneus vs BMD of the spine and proximal femur in the prediction of osteoporotic spine fractures. Eur Radiol 12:401-408.
145. Wehrli FW, Gomberg BR, Saha PK, Song HK, Hwang SN, Snyder PJ 2001 Digital topological analysis of in vivo magnetic resonance microimages of trabecular bone reveals structural implications of osteoporosis. J Bone Miner Res 16:1520-1531.
146. Wehrli FW, Hilaire L, Fernandez-Seara M, Gomberg BR, Song HK, Zemel B, Loh L, Snyder PJ 2002 Quantitative magnetic resonance imaging in the calcaneus and femur of women with varying degrees of osteopenia and vertebral deformity status. J Bone Miner Res 17:2265-2273.
147. Boutroy S, Bouxsein ML, Munoz F, Delmas PD 2005 In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab 90:6508-6515.
148. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD 2007 Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: The OFELY Study. J Bone Miner Res 22:425-433.
149. Melton LJ, Riggs BL, van Lenthe GH, Achenbach SJ, Muller R, Bouxsein ML, Amin S, Atkinson EJ, Khosla S 2007 Contribution of in vivo structural measurements and load/strength ratios to the determination of forearm fracture risk in postmenopausal women. J Bone Miner Res 22:1442-1448.
150. Chesnut CH III, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L 2005 Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results from the QUEST study. J Bone Miner Res 20:1548-1561.
151. Benito M, Vasilic B, Wehrli FW, Bunker B, Wald M, Gomberg B, Wright AC, Zemel B, Cucchiara A, Snyder PJ 2005 Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res 20:1785-1791.
152. Turner M, Clough R, Martin H, Topp L 1956 Stiffness and deflection analysis of complex structures. J Aeronautic Sci 23:805-823.
153. Faulkner K, Cann C, Hasedawa B 1991 Effect of bone distribution on vertebral strength: Assessment with a patient-specific nonlinear finite element analysis. Radiology 179:669-674.
154. Keyak JH, Meagher JM, Skinner HB, Mote CD Jr 1990 Automated three-dimensional finite element modelling of bone: A new method. J Biomed Eng 12:389-397.
155. Keyak JH, Fourkas MG, Meagher JM, Skinner HB 1993 Validation of an automated method of three-dimensional finite element modelling of bone. J Biomed Eng 15:505-509.
156. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA 2007 Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149-157.
157. Morgan EF, Bouxsein ML 2005 Use of finite element analysis to assess bone strength. BoneKEy-Osteovision 2:8-19.
158. Keyak JH, Rossi SA, Jones KA, Skinner HB 1998 Prediction of femoral fracture load using automated finite element modeling. J Biomech 31:125-133.
159. Keyak JH, Kaneko TS, Tehranzadeh J, Skinner HB 2005 Predicting proximal femoral strength using structural engineering models. Clin Orthop 437:219-228.
160. Keaveny T, Hoffman P, Kopperdahl D, Donley D, Krohn K, Glass EV, Mitlak BH 2007 Comparison of the effects of teriparatide and alendronate on parameters of total hip strength as assessed by finite element analysis: Results from the Forteo and Alendronate comparison trial. J Bone Miner Res 22:S1;S26.